CJC-1295 No DAC + Ipamorelin 10mg – Research Peptide Blend

CJC-1295 No DAC + Ipamorelin 10mg is a two-component research peptide blend containing 5mg CJC-1295 without DAC and 5mg Ipamorelin, providing 10mg of total peptide content per vial.

The combination is of research interest because the two peptides are associated with distinct signaling systems within the growth hormone axis. CJC-1295 without DAC is studied as a GHRH-related peptide analogue, while Ipamorelin is studied in connection with the growth hormone secretagogue receptor (GHSR) pathway. Research laboratories can therefore investigate the interaction and downstream signaling associated with these distinct peptide systems in controlled experimental models.

This product is supplied as research-grade lyophilized powder in a sterile multidose vial with a stated purity of ≥99%.

Product Specifications

• Contents: CJC-1295 (without DAC) 5mg + Ipamorelin 5mg
• Total Peptide Content: 10mg
• Purity: ≥99%
• Format: Lyophilized powder
• Grade: Research Grade
• Packaging: Sterile multidose vial
• Storage: 2°C–8°C
• Storage Protection: Protect from heat, moisture, and direct sunlight

The fixed 5mg + 5mg composition provides researchers with a defined two-peptide formulation for laboratory studies examining the interaction between GHRH-related and GHSR-related signaling pathways.

What Is CJC-1295 Without DAC + Ipamorelin?

CJC-1295 without DAC and Ipamorelin are two different synthetic research peptides that are frequently investigated within the broader field of growth hormone signaling.

CJC-1295 without DAC is commonly identified in research materials as a modified GHRH-related peptide, also referred to as Modified GRF(1-29). Research involving this peptide focuses on GHRH receptor-related signaling and the somatotropic axis.

Ipamorelin is a peptide studied for its interaction with the growth hormone secretagogue receptor (GHSR). Research materials commonly describe it as a selective GHSR agonist used to investigate receptor signaling and related cellular responses.

When studied together, these two compounds provide a research model for examining complementary signaling pathways associated with the growth hormone axis.

Current research-peptide listings in Canada commonly describe the 5mg/5mg combination as a dual-component research blend targeting GHRHR and GHSR-related pathways.

Research Applications

The CJC-1295 Ipamorelin research peptide combination may be relevant to laboratory research involving:

Growth Hormone Signaling Research

Researchers can investigate signaling associated with GHRH-related and growth hormone secretagogue pathways under controlled experimental conditions.

Receptor Pharmacology

The two peptides provide an opportunity to study distinct receptor systems and examine their respective contributions to downstream signaling.

Somatotropic Axis Research

The somatotropic axis is a major area of endocrinology and cellular signaling research. CJC-1295 without DAC and Ipamorelin are both investigated within this research field.

Cellular Signaling Studies

Laboratory models can be used to examine downstream molecular signaling and cellular responses associated with peptide-receptor interactions.

Metabolic Pathway Research

Research involving growth-hormone-related signaling may also examine associated metabolic pathways and cellular responses. Any such findings depend on the specific experimental model and should not be interpreted as established effects in humans.

Comparative Peptide Research

The 5mg + 5mg formulation can also be relevant to comparative studies investigating individual peptides versus combined peptide exposure.

Why Use a Defined 5mg + 5mg Research Blend?

A fixed composition can simplify experimental design by providing a consistent nominal quantity of each research peptide within the same vial.

This allows qualified researchers to work with a defined formulation when investigating questions involving:

• GHRH-related signaling
• GHSR-related signaling
• Receptor interaction studies
• Peptide pharmacology
• Cellular signaling pathways
• Somatotropic-axis research
• Comparative peptide experiments

The combination should be evaluated according to the specific research protocol, analytical methodology, and experimental model being used.

Research-Grade Quality

BioMatrix Compounds supplies this CJC-1295 No DAC + Ipamorelin formulation with a stated purity of ≥99%.

The peptides are supplied as lyophilized powder in a sterile multidose vial. A defined product specification is important for laboratory research because researchers require consistent research materials when conducting controlled experiments and comparing results across samples or experimental conditions.

Researchers should consult the applicable batch documentation and Certificate of Analysis where available before incorporating research material into an experimental workflow.

Storage

Store the sealed lyophilized product under refrigerated conditions at 2°C–8°C.

Protect the vial from:

• Excessive heat
• Moisture
• Direct sunlight
• Uncontrolled environmental conditions

Researchers should maintain appropriate laboratory storage records and follow their institution’s validated procedures for research materials.

CJC-1295 No DAC + Ipamorelin Research in Canada

BioMatrix Compounds provides this product strictly as a research compound. It is not marketed as a medication, dietary supplement, cosmetic, food product, or therapeutic product.

Canadian researchers and institutions should independently confirm the regulatory requirements applicable to their intended research activities.

Health Canada currently identifies CJC-1295 and ipamorelin among unauthorized injectable peptide drugs and states that injectable peptide drugs are regulated as prescription drugs in Canada. Health Canada’s April 2026 advisory also notes that unauthorized peptide products have not been assessed for safety, efficacy, or quality by Health Canada.

Accordingly, the research-use positioning of this product should not be interpreted as authorization for human or veterinary administration.

Related Research Compounds

Researchers exploring peptide signaling pathways may also be interested in other BioMatrix Compounds research materials.

A natural internal-link opportunity is the KPV 10mg research peptide, particularly for researchers working across different peptide-signaling models. Another relevant product connection is CJC-1295 without DAC as a standalone research compound, allowing researchers to distinguish single-compound research from combination-blend studies.

Research Use Only Disclaimer

For Research Use Only.

This product is intended exclusively for laboratory research and analytical purposes. Not for human or veterinary use.

This product is not intended for consumption, diagnosis, treatment, cure, or prevention of any disease or medical condition. No information on this page should be interpreted as medical advice, therapeutic guidance, dosage guidance, or a recommendation for personal use.

Researchers are responsible for determining whether the product is appropriate for their intended laboratory application and for complying with all applicable federal, provincial, institutional, and laboratory requirements.

CJC-1295 No DAC + Ipamorelin 10mg — 5mg + 5mg | ≥99% Purity | Research Grade